↓ Skip to main content

Dove Medical Press

The Flavagline Compound 1-(2-(dimethylamino)acetyl)-Rocaglaol Induces Apoptosis in K562 Cells by Regulating the PI3K/Akt/mTOR, JAK2/STAT3, and MAPK Pathways

Overview of attention for article published in Drug Design, Development and Therapy, August 2022
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

twitter
4 X users

Citations

dimensions_citation
2 Dimensions

Readers on

mendeley
6 Mendeley
Title
The Flavagline Compound 1-(2-(dimethylamino)acetyl)-Rocaglaol Induces Apoptosis in K562 Cells by Regulating the PI3K/Akt/mTOR, JAK2/STAT3, and MAPK Pathways
Published in
Drug Design, Development and Therapy, August 2022
DOI 10.2147/dddt.s357891
Pubmed ID
Authors

Xinmei Yang, Xijun Wu, Xiaosen Wu, Lei Huang, Jingrui Song, Chunmao Yuan, Zhixu He, Yanmei Li

X Demographics

X Demographics

The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 6 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 6 100%

Demographic breakdown

Readers by professional status Count As %
Unspecified 2 33%
Lecturer > Senior Lecturer 1 17%
Unknown 3 50%
Readers by discipline Count As %
Unspecified 2 33%
Biochemistry, Genetics and Molecular Biology 1 17%
Unknown 3 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 August 2022.
All research outputs
#16,277,849
of 26,169,168 outputs
Outputs from Drug Design, Development and Therapy
#908
of 2,295 outputs
Outputs of similar age
#212,348
of 437,242 outputs
Outputs of similar age from Drug Design, Development and Therapy
#12
of 56 outputs
Altmetric has tracked 26,169,168 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,295 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.5. This one has gotten more attention than average, scoring higher than 58% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 437,242 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 49th percentile – i.e., 49% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 56 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 75% of its contemporaries.